Renaissance Technologies LLC Buys New Position in Novavax, Inc. $NVAX

Renaissance Technologies LLC purchased a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 497,383 shares of the biopharmaceutical company’s stock, valued at approximately $4,049,000.

A number of other institutional investors and hedge funds have also bought and sold shares of NVAX. State Street Corp boosted its holdings in Novavax by 32.3% during the 4th quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after acquiring an additional 2,326,927 shares during the last quarter. UBS Group AG lifted its position in shares of Novavax by 40.3% during the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock valued at $32,890,000 after purchasing an additional 1,405,981 shares in the last quarter. Monaco Asset Management SAM lifted its position in shares of Novavax by 161.3% during the fourth quarter. Monaco Asset Management SAM now owns 1,045,000 shares of the biopharmaceutical company’s stock valued at $7,022,000 after purchasing an additional 645,000 shares in the last quarter. Barclays PLC boosted its holdings in Novavax by 108.8% during the fourth quarter. Barclays PLC now owns 1,102,300 shares of the biopharmaceutical company’s stock worth $7,407,000 after purchasing an additional 574,263 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in Novavax during the third quarter worth about $3,874,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

Novavax Stock Up 2.7%

NASDAQ NVAX opened at $7.95 on Friday. The company has a market cap of $1.31 billion, a PE ratio of -5.23 and a beta of 2.46. Novavax, Inc. has a 52 week low of $6.20 and a 52 week high of $11.97. The firm’s 50-day simple moving average is $8.72 and its two-hundred day simple moving average is $8.97.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm had revenue of $56.70 million during the quarter, compared to the consensus estimate of $52.51 million. During the same quarter last year, the company earned $0.62 earnings per share. The company’s revenue was down 76.2% on a year-over-year basis. As a group, equities research analysts anticipate that Novavax, Inc. will post -0.31 EPS for the current year.

Wall Street Analysts Forecast Growth

NVAX has been the subject of several analyst reports. TD Cowen increased their price objective on shares of Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Zacks Research upgraded Novavax from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a report on Tuesday. Wall Street Zen lowered Novavax from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Finally, BTIG Research reiterated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.00.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.